SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 272 participants.
Also called NCT02959606
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 272 participants
- Registry
-
NCT02959606
-
- Other papers using this trial's data
- A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02959606. Randomized; no masking; primary purpose treatment. Start 2016-12 (registry gives no type); primary completion 2019-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- Sarpogrelate SR 300mg
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Seoul National University Hospital
Record details
- Record id
cardio:ct-nct02959606- Content hash
7c0ed9d31545ecf7ca25e2675458dc240e1703242b999cdf187cd54952c396dc